Sandra Hoogerwerf
,
MD
Dr. Sandra Hoogerwerf graduated cum laude with a Doctorate of Medicine from the Erasmus University in Rotterdam, The Netherlands. She subsequently completed her internal medicine residency at Johns Hopkins Bayview Medical Center in Baltimore, Maryland and her clinical gastroenterology fellowship at the University of Texas Medical Branch in Galveston, Texas. In addition, she completed a gastroenterological research fellowship at the Johns Hopkins University in Baltimore, Maryland. Before joining Borland Groover in 2010, she served as an assistant professor of medicine at the University of Michigan Medical Center in Ann Arbor, Michigan.
Dr. Hoogerwerf has a longstanding interest in women’s health issues, functional bowel and motility disorders. She has published on a variety of topics including the management of gastrointestinal disease in pregnancy, acid suppressive therapy and reflux disease, irritable bowel syndrome and motility disorders such as achalasia.
Hoogerwerf WA, Hawkins AL, Perlman E, Griffin CA. Chromosome Analysis of Nine Osteosarcomas.Genes, Chromosomes & Cancer 9:88 - 92, 1994
Hoogerwerf WA, Tsao SC, Devuyst O, Levine SA, Yun CH, Yip JW, Cohen ME, Wilson PD, Lazenby AJ, Tse CM, Donowitz M. NHE2 and NHE3 are Human and Rabbit Intestinal Brush Border Proteins. American Journal of Physiology 33 (1): G29-41, 1996
Khurana S, Kreydiyyeh S, Arazon A, Hoogerwerf WA, Rhee SG, Donowitz M, Cohen ME. Asymmetric signal transduction in polarized ileal Na(+) absorbing cells. Biochemical Journal 313:509-18, 1996
Hoogerwerf WA, Soloway RD. Epidemiology, pathogenesis, and treatment of gallstones. Current Opinion in Gastroenterology 14:413-416, 1998
Hoogerwerf WA, Pasricha PJ, Kalloo AN, Schuster MM. Pain- The overlooked symptom in gastroparesis. American Journal of Gastroenterology 94:1029-1033, 1999
Hoogerwerf WA, Pasricha PJ. Botulinum Toxin and the Gut: From Toxin to Therapy. Clinical Perspectives in Gastroenterology 2:165-170, 1999
Hoogerwerf WA, Pasricha PJ. Taking control of fecal incontinence: early results of an artificial sphincter device. Gastroenterology 116:1005-1006, 1999
Hoogerwerf WA, Soloway RD. Gallstones. Current Opinion in Gastroenterology 15:442-447, 1999
Hoogerwerf WA, Pasricha PJ. Achalasia: treatment options revisited. Review. The Canadian Journal of Gastroenterology 14(5):406-409, 2000
Hoogerwerf WA, Soloway RD. Gallstones. Current Opinion in Gastroenterology 16(5):450-452, 2000
Hoogerwerf WA, Zou L, Shenoy M, Sun D, Micci MA, Lee Hellmich H, Xiao SY, Winston JH, Pasricha PJ. The proteinase-activated receptor 2 is involved in nociception. The Journal of Neuroscience 21(22); 9036-9042, 2001
Hoogerwerf WA, Pasricha PJ. Botulinum Toxin for Achalasia: Are We Asking the Right Questions? Digestive & Liver Disease 34(2):97-98, 2002
Hoogerwerf WA, Lee Hellmich H, Micci MA, Zou L, Winston JH, Pasricha PJ. Molecular cloning of the rat proteinase-activated receptor 4. BMC Molecular Biology 3:2, 2002
Hoogerwerf WA, Pasricha PJ. A decade of botulinum toxin injections for achalasia; where do we stand? Endoscopy 34(7):580-581, 2002
Hoogerwerf WA , Pasricha PJ. Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis. Commentary. ACP Journal Club. May-June;136, 2002
Hoogerwerf WA, Shenoy M, Winston JH, Xiao SY, He Z, Pasricha PJ. Trypsin mediates nociception via the proteinase-activated receptor 2 - A potentially novel role in pancreatic pain. Gastroenterology 127; 883-891, 2004
Hoogerwerf WA, Gondesen K, Xiao SY, Winston JH, Willis WD, Pasricha PJ. The role of mast cells in the pathogenesis of pain in chronic pancreatitis. BMC Gastroenterology 5:8, 2005
Hoogerwerf WA. Therapeutic management of pancreatitis. Current Opinion in Pharmacology 5(6):578-82, 2005
Hoogerwerf WA. Prokineticin 1 inhibits spontaneous giant contractions in the murine proximal colon through nitric oxide release. Neurogastroenterol Motil 18(6):455-63, 2006
Hoogerwerf WA, Sarna SK. Tachykinin receptors as drug targets for motility disorders. Digestive Diseases 24:1-8, 2006
Hoogerwerf WA. Biological Clocks and the Gut. Current Gastroenterology Report 8(5):353-9, 2006
Hoogerwerf WA, Hellmich HL, Cornelissen G, Halberg F, Shahinian VB, Bostwick J, Savidge TC, Cassone VM. Clock gene expression in the murine gastrointestinal tract: endogenous rhythmicity and effects of a feeding regimen. Gastroenterology 133:1250-1260, 2007
Olah A, Jozsa R, Csernus V, Sandor J, Muller A, Zeman M, Hoogerwerf W, Cornélissen G, Halberg F. Stress, geomagnetic disturbance, infradian and circadian sampling for circulating corticosterone and models of human depression? Neurotox Res. 13(2):85-96, 2008
Hoogerwerf WA, Sinha M, Conesa A, Luxon BA, Shahinian VB, Cornélissen G, Halberg F, Bostwick J, Timm J, Cassone VM. Transcriptional Profiling of mRNA Expression in the Mouse Distal Colon. Gastroenterology 135(6):2019-29, 2008
Hoogerwerf WA. Role of biological rhythms in gastrointestinal health and disease. Rev Endocr Metab Disord. 10:293–300, 2009
Hoogerwerf WA, Shahinian VB, Cornélissen GG, Halberg F, Bostwick J, Timm J, Bartell PA, Cassone VM. Rhythmic changes in colonic motility are regulated by period genes. Am J Physiol Gastrointest Liver Physiol 298(2):G143-50, 2010
Bostwick J, Nguyen D, Cornélissen GG, Halberg F, Hoogerwerf WA. Effects of acute and chronic STZ-induced diabetes on clock gene expression and feeding in the gastrointestinal tract. Mol Cell Biochem [in press] PMID: 20091094, 2010
Nojkov B, Rubenstein JH, Chey WD, Hoogerwerf WA. The impact of rotating shift work on the prevalence of Irritable Bowel Syndrome in nurses. Am J Gastroenterol [in press] PMID: 20160712, 2010
Donowitz M, Levine SA, Yun CH, Brant SR, Nath S, Yip J, Hoogerwerf S, Pouysségur J, Tse CM. In: Molecular Biology of Membrane transport Disorders. Chapter 14: 259-276, Schultz SG et al (ed), Plenum Press, New York, NY, 1996
Hoogerwerf WA, Pasricha PJ. Botulinum injection for spastic disorders. In: Baillere’s Clinical Gastroenterology 13(1):131-143, Allescher HD, Classen M (Eds), Harcourt Health Sciences, London, UK, 1999
Hoogerwerf WA, Pasricha PJ. Pneumatic dilatation and Botulinum Toxin injection for achalasia. In: UpToDate, Rose BD (Ed), Wellesley, MA, 2000
Hoogerwerf WA, Pasricha PJ. Agents used for control of gastric acidity and treatment of peptic ulcers and gastroesophageal reflux disease. In: Goodman and Gilman’s. Section 6, pgs1005-1020. The Pharmacological Basis of Therapeutics. Hardman JG, Limbird LE (Eds), McGraw-Hill, New York, NY, 2001
Hoogerwerf WA, Pasricha PJ. Pharmacologic therapy in treating achalasia. In: Gastrointestinal Endoscopy Clinics of North America 11(2): 311-323, RKH Wong (Ed), WB Saunders, Philadelphia, PA, 2001
Hoogerwerf WA, Pasricha PJ. Achalasia and other motor disorders. In: Gastrointestinal disease. An endoscopic approach. Chapter 19; pg 299-330. DiMarino AJ, Benjamin SB (Eds), Slack Inc, Thorofare, NJ, 2002
Hoogerwerf WA, Dykstra DD, Pasricha PJ. Botulinum Toxin for Achalasia and Related Disorders. In: Scientific and Therapeutic Aspects of Botulinum Toxin. Chapter 28; pg 295-302. Brin MF, Hallet M, Jankovic J (Eds) (A WE MOVE Publication). Lippincott, Williams, and Wilkins, Philadelphia, PA, 2002
Hoogerwerf WA, Pasricha PJ. Chronic abdominal pain. In: Advanced therapy in Gastroenterology and Liver Disease. Bayless TM and Diehl AM (Eds). BC Decker Inc Publisher, 2004